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We previously reported the development of a human monoclonal antibody (CS-D7,
IgG1) with specificity and affinity for the iron regulated surface determinant B (IsdB) of
Staphylococcus aureus. CS-D7 mediates opsonophagocytic killing in vitro and protection
in a murine sepsis model. In light of recent data indicating that IsdB specific T cells (CD4+,
Th17), not Ab, mediate protection after vaccination with IsdB, it is important to investigate
the mechanism of protection mediated by CS-D7. The mAb was examined to determine if
it blocked heme binding to IsdB in vitro. The mAb was not found to have heme blocking
activity, nor did it prevent bacterial growth under in vivo conditions, in an implanted growth
chamber. To assess the role of the mAb Fc a point mutation was introduced at aa 297
(CS-D7·N297A). This point mutation removes Fc effector functions. In vitro analysis of
the mutein confirmed that it lacked measurable binding to FcγR, and that it did not fix
complement. The mutein had dramatically reduced in vitro opsonic OP activity compared
to CS-D7. Nonetheless, the mutein conferred protection equivalent to the wild type mAb
in the murine sepsis model. Both wild type and mutein mAbs were efficacious in FcγR
deletion mice (including both FcγRII−/− mice and FcγRIII−/− mice), indicating that these
receptors were not essential for mAb mediated protection in vivo. Protection mediated by
CS-D7 was lost in Balb/c mice depleted of C3 with cobra venom factor (CFV), was lost in
mice depleted of superoxide dismutase (SOD) in P47phox deletion mice, and as previously
reported, was absent in SCID mice (Joshi et al., 2012). Enhanced clearance of S. aureus in
the liver of CS-D7 treated mice and enhanced production of IFN-γ, but not of IL17, may play
a role in the mechanism of protection mediated by the mAb. CS-D7 apparently mediates
survival in challenged mice through a mechanism involving complement, phagocytes, and
lymphocytes, but which does not depend on interaction with FcγR, or on blocking heme
uptake.
Keywords: iron regulated surface determinant B (IsdB), Staphylococcus aureus, vaccination, passive immunization,
opsonophagocytosis
INTRODUCTION
Staphylococcus aureus is a significant cause of hospital acquired
bloodstream and catheter infections (Thwaites et al., 2011), and
is a leading cause of endocarditis, osteomyelitis, and skin and
soft tissue infections (Lowy, 1998a). Although it has been exten-
sively investigated, natural protective immunity against S. aureus
is poorly understood. Acute infection with S. aureus does not
Abbreviations: IsdB, iron regulated surface determinant B; OP, opsonophago-
cytic uptake activity; CVF, cobra venom factor; IC, immune complexes; ECD,
extracellular domains.
prevent re-infection with this bacteria (Lee, 1996). Preclinical
and clinical data indicate that immunization with intact bacteria
induces high serum antibody immune titers to staphylococcus,
but does not confer protection against S. aureus infection (Lee,
1996; Schaffer and Lee, 2008). In vivo bacterial clearance is
currently believed to be facilitated by antibody (Ab) and com-
plement mediated uptake and killing by phagocytes (Peterson
et al., 1978; Leijh et al., 1981; Verbrugh et al., 1982; Gregory
et al., 1996; Verdrengh and Tarkowski, 1997; Cunnion et al.,
2004). S. aureus is a commensal species that colonizes peo-
ple transiently or permanently, and therefore, individuals have
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antibodies to S. aureus. Iron regulated surface determinant B
(IsdB) is an antigen expressed on the cell surface of S. aureus in
iron limited environments, with a MW of approximately 72 kD.
Its function is to capture and import heme iron from hemoglobin
(Mazmanian et al., 2003). Due to the low iron environment of
mammalian blood and tissue, IsdB is upregulated during infec-
tion in vivo (Brown et al., 2009). Humans, as well as mammals
examined to date, have pre-existing antibody titers to IsdB (Lowy,
1998b), but it is unknown whether these pre-existing titers offer
protection.
We previously reported the development of a fully human
monoclonal antibody (CS-D7, IgG1) specific for IsdB of
Staphylococcus aureus (Ebert et al., 2010). The mAb was isolated
from the Cambridge Antibody Technology (CAT) scFv antibody
library and has high affinity and specificity for IsdB. It recognizes
a conformational epitope spanning amino acids 50–285 of the
antigen. As reported, this mAb had functional activity in vitro
(opsonophagocytic killing activity) and significantly enhanced
survival in the murine sepsis model in Balb/c mice. In recent
work, Joshi and co-authors demonstrated that T cells not B cells
were the critical effector cells conferring enhanced survival fol-
lowing S. aureus challenge in the Balb/c murine sepsis model
(Joshi et al., 2012). Using IsdB specific lymphocytes adoptively
transferred from wild type into SCID mice, enhanced survival
was determined to be mediated entirely by IsdB specific CD4+
T cells, with B cells and Ab playing no measurable role. This
observation, that IsdB specific Ab does not play a critical role in
the model, is in apparent disagreement with previously published
data indicating that enhanced survival in the murine sepsis model
correlates with anti-IsdB Ab titers (Kuklin et al., 2006) and with
data indicating that Ab can confer enhanced survival in the same
Balb/c sepsis model (Brown et al., 2009; Kim et al., 2010). We,
therefore, sought to investigate the protective mechanism of mAb
CS-D7 in the murine sepsis model. Since this model is routinely
used to verify the efficacy of vaccine antigens targeting S. aureus
(Fattom et al., 1996; Kuklin et al., 2006; Stranger-Jones et al., 2006;
Vernachio et al., 2006; Spellberg et al., 2008), it is important to
define the meaning of immune mediated enhanced survival in
this important animal model.
We found that although CS-D7 mediates enhanced survival
in the murine sepsis model, that activity was most likely not
dependent on direct inhibition of bacterial growth or survival, or
onpreventionof thephysiological functionofIsdB.Weinvestigated
the role of themAb Fc and found that amutein lacking Fc function
conferred equivalent survival to the wild type mAb in the murine
sepsis model. This was a surprising finding, as the mechanism of
antigen specific mAb mediated bacterial clearance is thought to
rely on engagement of the receptors for complement and Fcγ by
C3bor iC3b andAbbound to thebacteria surface.The engagement
of both the Fcγ receptor and the CR1 receptor, leads to synergy
of bacteria uptake and killing by effector cells (Philippe, 2004;
Roozendaal and Carroll, 2006). We investigated the role of other
components necessary for bacterial clearance in vivo, and found
that complement and phagocytes were necessary for protection
mediated by CS-D7 in Balb/c mice. CS-D7 mediated survival in
the sepsis model is dependent on the presence of lymphocytes
(Joshi et al., 2012), therefore, lymphocytesmaycontributeessential
cytokines for stimulation of a strong phagocyte killing response.
It was determined that CS-D7 may enhance survival through a
non-classical Ab mediated uptake/killing mechanism. A possible
mechanism will be discussed.
MATERIALS ANDMETHODS
RECOMBINANT PROTEINS
Recombinant IsdB was prepared as previously described (Kuklin
et al., 2006). Heme-free IsdB was prepared by isolation from
recombinant heme containing IsdB following peak separation on
a cation binding gel resin. Separation of the two fractions of
IsdB was readily made by following the absorbance at 280 nm for
the presence of protein, and at 400 nm for the presence of iron
containing IsdB. The extracellular domains (ECDs) of FcγRIIA
and FcγRIIIA were expressed recombinantly in Pichia pastoris
at Merck/MSD (Rahway, NJ) (Li et al., 2006). After filtration,
the FcγR’s were isolated by Ni2+ affinity columns and further
purified by hydrophobic interaction chromatography. SDS-PAGE
electrophoresis indicated the proteins were of the correct molec-
ular weight and the ability of the FcγR ECD’s to bind mAbs was
confirmed by surface plasmon resonance.
To construct the antibody Fc variant CS-D7· N297A, muta-
genic primers were designed and synthesized. Mutant clones
were generated through PCR and transformation steps by
using QuikChange Lightning Site-Directed Mutagenesis kit and
QuikChange Lightning Multi Site-Directed Mutagenesis kit
(Stratagene, Santa Clara, CA). Commercially available antibod-
ies were acquired and used as supplied by the manufacturer.
Additional antibodies were produced by transient transfection in
CHO or HEK cells (Sino Biological, Beijing, China) (Ebert et al.,
2010). Antibodies were stored in 6% sucrose, 100mM arginine,
100mM histidine, pH 6.0.
BACTERIA
The following strains were used in this investigation: S. aureus
Becker (obtained from Chia Lee, University of Arkansas, MSSA,
spa type 715, CC45), SA025 (clinical isolate from pancreatic cyst,
MRSA, SCCmec IV, spa type 785, CC22), and 8325-4 spa minus
(obtained from Intercell AG). Bacteria were grown on tryptic soy
agar (TSA), or tryptic soy broth (TSB) overnight, pelleted and
stored as frozen 15% glycerol stocks. Alternatively, bacteria were
passaged two to three times to stationary phase in iron restricted
medium (<0.1mg/L), Roswell Park Memorial Institute (RPMI)
1640medium (Life Technologies, Grand island, NY), pelleted and
stored frozen in 15% glycerol. For use in experiments, bacteria
were thawed, pelleted, and resuspended in the appropriate buffer
or medium.
MICE
Balb/c, P47 phox−/− (B6.129S2-Ncf1tm1shl N14) missing a key
component of the superoxide generating system, and FcγRII−/−
(Fcgr2b; C129S4(B6)-Fcgr2btm1Ttk/cAnNTac N12; Balb/c back-
ground) missing the FcγRIIγ protein; and FcγRI−/− (Fcer1g;
C.129P2(B6)-Fcerlgtm1RavN12; Balb/c background) missing the
γ chain subunit of the Fc receptors, were obtained from Taconic
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(Hudson, NY), and housed in micro-isolator cages during exper-
iments.
GROWTH OF S. aureus IN CHAMBERS IMPLANTED IN RATS
In vivo growth of S. aureus Becker was investigated using growth
chambers implanted sub-dermally on the back of rats (n = 12).
The growth chambers were made from sterile dialysis tubing,
with a MW cutoff of 50 kDa, and with a volume of 1mL. To
investigate whether mAb could inhibit the survival and growth
of S. aureus Becker, 1.4 × 106 CFU bacteria (from TSA culture)
with or without 1 mg of mAb, was added to growth chambers.
It was previously determined that IsdB specific mAb binding to
5 × 106 CFU of IsdB expressing S. aureus Becker is saturated at
approximately 5μg (Brown et al., 2009). Therefore, the bacteria
were exposed to a large excess of antibody during growth in the
chamber. At designated times, rats (n = 3–4) were sacrificed and
growth chambers removed aseptically. Bacteria were harvested
and colony counts (CFU/mL) were obtained through serial dilu-
tion of the bacterial culture followed by plating on TSA overnight
at 37◦C.
HEME BINDING UPTAKE ASSAY
See Supplemental Data.
IgG/Fcγ RECEPTOR BINDING ASSAY
FcγR ELISA binding assays were performed as previously
described (Shields et al., 2001) with minor modifications.
Human FcγRIIA ECD (1μg/mL) or human FcγRIIIA ECD
(2μg/mL) diluted in PBS was coated overnight at 4◦C in white
96-well Maxisorp plates (Nunc, Rochester, NY). The plates
were washed three times (BioTek ELX405) with PBS (phosphate
buffered saline) containing 0.05% Tween20. Serial dilutions
of the test antibodies in blocking buffer [2% BSA (Jackson
ImmunoResearch Laboratories, West Grove, PA) in SuperBlock
T20 (Pierce, Rockford, IL)] were added for 90min with rock-
ing. After washing, bound antibodies were labeled with either
0.1μg/mL (for FcγRIIA) or 1μg/mL (for FcγRIIIA) of biotiny-
lated anti-κ light chain F(ab′)2 (Southern Biotech, Birmingham,
AL) followed by 100 ng/mL of Streptavidin-Europium
(PerkinElmer, Waltham, MA). Time-resolved fluorescence
was measured by a Victor3 spectrophotometer (Perkin-Elmer,
CityplaceWaltham, StateMA) and the relative fluorescence was
plotted versus the log of the antibody concentration.
COMPLEMENT C3b DEPOSITION ASSAY
An in vitro cell free C3b deposition assay was developed to mea-
sure functional complement activation dependent on IgG-C1q
binding. High binding microtiter plates were coated with mAb
in PBS (12.5μg/mL) and incubated at 4◦C overnight. Plates
were blocked with 0.1% BSA in PBS for 2 h at room temper-
ature, and washed with PBS containing Ca2+ and Mg2+. C1q
(Calbiochem, EMD Chemicals, USA) was serially diluted into
C1q depleted human serum (Quidel). The mix was added to
the mAb coated microtiter plate and incubated 30min at room
temperature. C3b was detected by addition of sheep antihuman
C3b-FITC (Accurate Chemical and Scientific Corp., Westbury,
NY) to each well for 1 h at room temperature. Assay readout was
measured at 535 nm.
OPSONOPHAGOCYTIC (OP) UPTAKE ASSAY
The OP assay has been described previously (Cope et al.,
2008). This assay measures Ab and complement mediated
opsonophagocytosis (uptake) by HL60 phagocytes, but not killing
by the phagocytes. Components for the assay were dimethyl-
formamide (DMF) differentiated HL60 cells, baby pig sera as
a source of complement, 5′-6′-FAM-SE fluorescently labeled,
iron starved S. aureus. In this flow cytometry based assay, non-
fluorescent HL60 cells were examined for the presence (via phago-
cytosis) of opsonized fluorescently labeled S. aureus 8325-4 (spa
minus), to determine OP activity of antibodies. The bacteria
strain used in the assay was chosen to avoid non-specific bind-
ing of antibody to the bacteria surface through binding to Protein
A. During assay development, it was determined that a spa pos-
itive strain (i.e., Becker) was found to have equivalent activity
to the 8325-4 strain, however for simplification of the assay and
interpretation of results, strain 8325-4 was routinely used. Briefly,
2.4 × 106 iron restricted bacteria were combined with antibod-
ies. After a short incubation of 30min, complement was added
to the mixture and incubated for an additional 30min at 37◦C.
Following this incubation the bacteria were washed and labeled
with FAM-SE. Then 2 × 105 HL60 cells were mixed with the bac-
teria at a ratio of 8 bacteria to 1 HL60 cell. The reaction mix was
incubated at 37◦C, 170 RPM for 30min. The HL60 phagocyto-
sis of bacteria was stopped by addition of cold PBS. The number
of HL60 cells containing engulfed bacteria was measured on a
FACSCalibur (Becton Dickinson).
PASSIVE IMMUNIZATION AND CHALLENGE MODELS
All animal work was performed in accordance with the Merck
Research Laboratories Institutional Animal Care and Use com-
mittee guidelines. Antibodies were evaluated for efficacy using
passive immunization of mice in the murine sepsis model (Brown
et al., 2009). In preliminary experiments, S. aureus SA025 (from
TSA culture) was titrated via i.v. injection to determine the LD80
dose for Balb/c mice. Next, mAb CS-D7 was dose titrated via i.p.
injection prior to i.v. challenge, to achieve approximately 80%
survival at day 4 post challenge (data not shown). The optimal
bacterial challenge inoculumwas determined to be approximately
2–3 × 108 CFU and the optimal antibody dose was 400μg. The
final model used was as follows; 400μg of antibody per mouse
(n = 5) was injected via the i.p. route 2 h prior to challenge
of bacteria strain SA025 (from TSA culture, 2–3 × 108 CFU)
via tail vein injection. Mice were monitored for survival for
96 h. Monitoring of survival for 96 h post challenge was chosen
because that time period reflected the largest differences between
experimental and control groups, and few mice died thereafter.
Data from three or more experiments were pooled for survival
analysis. To deplete mice of C3, mice were treated with CVF
(Cunnion et al., 2004). The amount of CVF was titrated to give
essentially no C3 in the murine sera. C3 was measured using a
murine ELISA for complement factor 3 (ALPCO™ Diagnostics,
Salem, NH).
MURINE CYTOKINE AND CFU MEASUREMENT
Mice (n = 20–24 per group) were injected i.p. with mAb fol-
lowed by i.v. S. aureus challenge as described above. Subgroups
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of 5–6 mice were sacrificed at designated time points and blood
and tissue collected. Organs were placed in 2 mL of cold PBS.
Blood and tissue reserved for cytokine measurement were imme-
diately frozen by placing on dry ice. Tissues were stored at −80◦C
until use, at which time they were removed, homogenized and
evaluated for cytokines. Murine cytokines were measured using
kits from MSD (Meso Scale Discovery, Inc., Gaithersburg, MD),
as per the manufacturer’s instructions. Tissues reserved for CFU
measurement were placed on wet ice and stored at 4◦C until
homogenized (in a total of 5mL PBS) and 50μL of homogenate
plated for CFU evaluation. As a control, survival of 10 mice was
observed for the duration of the experiment to ensure that the
cytokine and/or CFU data reflected conditions of efficacy of the
antibody. The experiments were performed two or more times
with representative data listed.
STATISTICAL METHODS
For comparison of survival in the murine challenge experiments,
results of individual survival experiments of mice were pooled
and curves were analyzed using the Prism® software (Prism for
Windows, version 5.01, GraphPad Software, Inc., La Jolla, CA),
and choosing the Log rank, Mantel Cox test statistical method for
testing significance. Comparisons of CFU/mL were made using
the two tailed unpairedT test with Prism® software. Comparisons
of cytokines/mL were made using the two tailed T test with
Windows, version 5.01, Excel® software.
RESULTS
mAb CS-D7 DOES NOT DIRECTLY INHIBIT GROWTH OF S. aureus
IN IMPLANTED CHAMBERS In vivo
It was previously reported that CS-D7 enhanced survival in the
murine lethal challenge model. To investigate the mechanism
of this activity, the potential for direct inhibition of growth
of S. aureus by the antibody was evaluated. Growth chambers
implanted sub-dermally on the back of rats were used to measure
outgrowth of the bacteria under conditions that induced expres-
sion of the antigen, that is, under iron restricted, but nutrient rich,
in vivo conditions. This method allowed quantitative and qualita-
tive analysis of the resulting bacteria. In preliminary experiments,
it was determined that S. aureus Becker (starting concentration
of 1 × 106 CFU) reached stationary phase at approximately 10–
12 h (at a concentration of 4–6 × 108 CFU), in these chambers
(Supplemental Data, Figure A1). It was also demonstrated that
there was rapid expression of IsdB by the bacteria, and >95%
of the bacteria expressed the antigen at 8 h after implantation in
the chamber (as demonstrated by flow cytometry, Supplemental
Data, Figure A1).
To investigate whether CS-D7 inhibited the survival and
growth of S. aureus under these conditions, bacteria plus an excess
of either mAb CS-D7 or 20C2HA (non-specific isotype matched
control mAb) were added to growth chambers (Figure 1). At sev-
eral time points (3–6 h), it was observed that the bacteria were
aggregated in the presence of mAb CS-D7, but not the presence
of control mAb 20C2HA. This most likely represents cross link-
ing of bacteria due to CS-D7 binding to IsdB expressed on the
bacteria surface. Aggregation may have contributed to an appar-
ently lower CFU/mL at the 6 h time point, due to the difficulty
FIGURE 1 | S. aureus growth in the presence of IsdB specific mAb or
isotype control mAb. Growth chambers containing 1 × 106 CFU Becker
and 1mg of mAb CS-D7 (inverted triangle), or 20C2HA, (closed circles), or
no mAb (open circles) were evaluated for outgrowth of bacteria during a
24h period. At designated times, a subset of rats were euthanized,
chambers removed and bacteria were quantified by serial dilution on TSA.
of making a single CFU suspension from aggregated bacteria for
serial dilution and plating. By 24 h, there were equivalent num-
bers of CFU in all three growth chamber conditions. Therefore,
although CS-D7 bound to S. aureus, this binding did not sig-
nificantly inhibit survival or division of the bacteria. Binding of
CS-D7 did lead to transient bacteria aggregation.
mAb CS-D7 DOES NOT MEASURABLY INHIBIT HEME UPTAKE
FROM HEMOGLOBIN In vitro
IsdB is a bacterial surface protein which functions to capture
heme, a source of iron, from hemoglobin for import into the
bacteria (Mazmanian et al., 2003). An antibody which could
block this function of the antigen might possess enhanced efficacy
against the bacteria (Kim et al., 2010). It is known that CS-D7
can bind equivalently to both heme free and heme replete IsdB
(unpublished data), indicating that the presence of heme does not
adversely affect the epitope which CS-D7 recognizes. To inves-
tigate potential mAb interference of heme uptake, an assay was
developed to determine if CS-D7 binding to heme free IsdBwould
prevent heme transfer from hemoglobin to the antigen (See
Supplemental Data and Supplemental Table A1). For this evalua-
tion, CS-D7 and control mAb 20C2HA were incubated separately
with IsdB− (heme free IsdB) and the complexes were exposed to
human hemoglobin immobilized on Sepharose®. Equal amounts
of protein samples were combined with the hemoglobin resin
(containing a 1:1 molar ratio of antibody to antigen) in each
case. As indicated in Table 1, the IsdB− in samples 1 and 2
bound heme after interaction with the hemoglobin-Sepharose®.
In addition to CS-D7, a second IsdB specific mAb was evalu-
ated, mAb 2H2 (Brown et al., 2009). The sample containing 2H2
plus IsdB−, and the sample containing CS-D7 plus IsdB−, had
equivalent A400/A280 ratios after exposure to hemoglobin (0.24
and 0.22 respectively), as the sample containing the non-specific
control mAb 20C2HA plus IsdB− (0.23). This indicated that
the presence of the two test mAbs did not prevent IsdB− from
binding heme, under these in vitro conditions. This result did
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Table 1 | Heme transfer from hemoglobin to heme minus IsdB (IsdB−) in the presence of mAbs.
Sample number Antibody added to IsdB− Absorbance A400 (iron)/A280 (protein); (ratio)
Starting sample (Antibody + IsdB−) Final, total column fractions
(Antibody + IsdB− + heme)
1. 20C2HA 0.05/2.97 (0.02) 0.80/3.55 (0.23)
2. CS-D7 0.03/2.64 (0.01) 0.64/2.89 (0.22)
3. 2H2 0.06/2.84 (0.02) 0.68/2.86 (0.24)
not rule out the possibility that CS-D7 and/or 2H2 caused the
heme iron to bind at a position other than the NEAT domain
(Grigg et al., 2007) of the antigen. Exposure of the hemoglobin-
Sepharose® to antibody alone did not result in binding of heme
to the mAb.
FUNCTIONALLY Fc DEFECTIVE MUTEIN CS-D7·N297A WAS
PREPARED FOR EVALUATION OF mAb OP ACTIVITY
Based on the above results, the mechanism of protection medi-
ated by CS-D7 may not involve direct growth suppression of
the bacteria, or inhibition of the physiological function of IsdB.
Therefore, experiments were devised to determine if CS-D7
enhanced uptake and killing of S. aureus in vivo. To this end, an
Fc mutant of CS-D7 (IgG1 isotype) was made. A point mutation
was introduced which converted amino acid 297 from asparagine
to alanine. Due to this mutation, the Fc cannot be glycosylated
and therefore, loses its binding activity for Fcγ receptors and C1q
(Lund et al., 1996). To verify that the mutein no longer bound
to Fc, an in vitro ELISA to measure Fc receptor binding was
employed, as described in Methods. Results from this assay indi-
cated that while CS-D7 had robust binding to the Fc receptors
tested, CS-D7·N297A had undetectable binding to either of the
two receptors FcγRIIa or FcγRIIIa (Figures 2A,B).
To verify that the mutein CS-D7·N297A had lost its abil-
ity to fix complement, an assay to measure C3b deposition was
developed. This assay measured the generation of C3b in C1q
replenished human serum, when incubated with mAb bound to
a microtiter plate surface. When CS-D7 was evaluated for com-
plement activation in this assay, robust generation of C3b was
observed (Figure 3), which was similar in quantity to the C3b
generated in the presence of licensedmAb Rituxan© (Genentech)
(Zhou et al., 2008; Pawluczkowycz et al., 2009). However, in the
presence of mutein CS-D7·N297A, generation of C3b was not
observed. This indicated that the classical pathway of complement
fixation, starting with binding of C1q to the Fc of the mAb, was
not activated by CS-D7·N297A.
OP activity was assessed in a third in vitro evaluation of
functionality of CS-D7·N297A since the first two assays used to
evaluate CS-D7·N297A were not cell based assays. Therefore, the
mutein was compared to wild type CS-D7 in an OP assay, in
the presence of HL60 phagocytic cells and fluorescently labeled
S. aureus, as described in Methods (Figure 4). In this assay, there
was a background level of approximately 20% fluorescent HL60
in the absence of antibody. The wild type CS-D7 had robust OP
activity. In the presence of the maximal amount of 10μg CS-
D7mAb/mL, there was an increase of 50% of HL60 containing
FIGURE 2 | CS-D7 or CS-D7·N297A mAb binding to FcγRIIa or FcγRIIIa.
Binding of mAbs to (A) FcγIIa or (B) FcγIIIa was measured as described in
Methods. Data shown are individual curves for triplet determinations.
phagocytosed bacteria, above background levels. At the same con-
centration, only 10% of HL60 in the presence of the isotype
control mAb, and 0% of HL60 in the presence of the mutein con-
tained phagocytosed bacteria above the background level. Both
the isotype control and the mutein raised levels of uptake to
approximately 20% above background at a 10-fold higher con-
centration of antibody, but further increases in concentration did
not increase uptake above that level. Therefore, in agreement with
the analysis above, the mutein had dramatically less functional
activity than the wild type mAb.
CS-D7 AND MUTEIN CS-D7·N297A CONFER EQUIVALENT
PROTECTION IN THE MURINE SEPSIS MODEL
After establishing that the mutein had significantly reduced Fc
functionality, the mutein and wild type mAbs were compared
for efficacy in the murine sepsis model. Balb/c mice were pas-
sively immunized with 400μg of CS-D7, or CS-D7·N297A, or
the isotype control 20C2HA. Mice (n = 5) were challenged via
the tail vein with S. aureus SA025, and were monitored for
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FIGURE 3 | Stimulation of complement C3b formation in human
plasma by mAbs CS-D7, CS-D7·N297A, or Rituxan©. Microtiter plates
coated with one of three mAbs were exposed to C1q serially diluted into
C1q deficient human sera. C3b generation was quantitated as described in
Methods. Data shown are the mean ± s.e. n = 3.
FIGURE 4 | OP activity mediated by mAbs CS-D7, CS-D7·N297A, or
isotype control 20C2HA. OP activity was measured by combining
differentiated HL60 with fluorescently labeled opsonized S. aureus,
incubating the mixture, and measuring HL60 with engulfed bacteria, as
described in the Methods section. Data shown are the mean ± s.e. n = 2.
survival for 96 h (Table 2). The experiment was repeated sev-
eral times and data were pooled for analysis. Unexpectedly, CS-
D7 and the mutein had equivalent activity in this model (P =
0.4852), and were significantly superior to the isotype control
mAb (P < 0.001).
CS-D7 AND CS-D7·N297A CONFER EQUIVALENT PROTECTION IN
FcR−/− MICE
Since the mutein was equally active in the murine sepsis model
to the wild type CS-D7, it appeared that binding to Fcγ receptors
and ability to fix complement were less important for the mecha-
nism of protection in this model. To further determine whether
binding to Fc receptors was non-essential for protection, mice
genetically deficient for either the activating receptor (Fcγ IIII) or
the inhibitory receptor (Fcγ RII) were investigated in the murine
sepsis model. Mice (n = 5) were passively immunized i.p. with
mAb prior to receiving a lethal dose of S. aureus via the tail
vein. The experiment was repeated four to five times and data
were combined for analysis. In these experiments, the wild type
and the mutein had equivalent activity (Tables 3 and 4), which
was significantly higher than for the control mAb 20C2HA. MAb
mediated survival was lower in these deletion murine strains than
in the wild type Balb/c mice. This is most likely due to increased
sensitivity of the mice to S. aureus challenge.
NEITHER CS-D7 NOR CS-D7·N297A CONFER PROTECTION IN THE
ABSENCE OF AN INTACT COMPLEMENT SYSTEM, OR IN THE
ABSENCE OF EFFECTOR CELLS WITH FUNCTIONING OXIDATIVE
BURST
To investigate whether the mechanism of CS-D7 efficacy in the
murine sepsis model depended on phagocytes and complement,
experiments were conducted to remove these components from
mice prior to challenge. In the first case, Balb/cmice were depleted
of C3 using CVF (Cunnion et al., 2004). CVF activates the alterna-
tive pathway and quickly depletes the host of C3, although not the
components of the classical pathway. Mice were passively immu-
nized and challenged as above. In mice depleted of C3, the mAbs
were not protective (Table 5). To effectively remove neutrophils
and other phagocytes with an oxidative burst mechanism from
playing a role in mAb mediated survival, P47 phox−/− mice lack-
ing a functional oxidative burstmechanism were employed. These
mice were passively immunized and challenged, but they were not
significantly protected by the mAbs (Table 6).
mAb CS-D7 SIGNIFICANTLY REDUCES CFU BURDEN IN LIVER,
BUT NOT IN OTHER ORGANS
To determine if CS-D7 enhanced bacteria clearance in the murine
model, Balb/c mice were passively immunized with CS-D7 or
isotype control mAb 20C2HA, or PBS alone, and challenged
as above. At designated time points, mice were sacrificed and
blood and organs were harvested. Due to increasing disease from
S. aureus challenge in control mice, mice were not evaluated
after 48 h post challenge for CFU burden. Survival was observed
until 96 h post challenge in a subgroup of 10 mice (survival
rate for CS-D7, 72%; 20C2HA, 28%; PBS, 39%). As shown in
Figure 5, there were no significant differences in the blood burden
(CFU/0.01mL) of the animals, nor in the bacteria burden in the
filter organs, with the exception of a significant reduction in the
liver of CS-D7 immunized animals at 1 h (P = 0.007) and 4 h post
challenge (P = 0.015). There was a trend of CS-D7 mediating
faster clearance in other organs, for example in the kidneys, but
this difference did not reach statistical significance (P > 0.05).
Interestingly there was an apparent higher level of CFU recovered
from the spleens of animals injected with CS-D7 than Ab control
animals at 48 h post challenge, however this difference was not
statistically significant, and was no different from the PBS control
animals.
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Table 2 | Comparison of mAb efficacy in the murine sepsis model.
mAb Number of Balb/c mice surviving Total (%) P
Hours post challenge
0 24 48 72 96
CS-D7 20 20 20 17 14 4 (70%) ∗<0.001
CS-D7·N297A 20 20 20 15 12 12 (60%) †0.4852
20C2HA 30 28 21 8 4 4 (13%)
∗Comparison of survival with CS-D7 versus survival with isotype control 20C2HA.
†Comparison of survival with CS-D7·N297A versus survival with CS-D7.
Table 3 | Passive immunization and challenge of FcγRIII−/− mice.
mAb Number of FcγIII−/− mice surviving Total (%) P
Hours post challenge
0 24 48 72 96
CS-D7 20 20 20 8 7 7 (35%) ∗0.002
CS-D7·N297A 20 20 18 7 6 6 (30%) †0.517
20C2HA 20 20 13 3 1 1 (5%)
∗Comparison of survival with CS-D7 versus survival with isotype control 20C2HA.
†Comparison of survival with CS-D7 ·N297A versus survival with CS-D7.
Table 4 | Passive immunization and challenge of FcγII−/− mice.
mAb Number of FcγII−/− mice surviving Total (%) P
Hours post challenge
0 24 48 72 96
CS-D7 20 19 16 16 11 11 (55%) ∗0.01
CS-D7·N297A 20 16 14 11 9 9 (45%) †0.34
20C2HA 20 14 9 6 5 5 (25%)
∗Comparison of survival with CS-D7 versus survival with isotype control 20C2HA.
†Comparison of survival with CS-D7·N297A versus survival with CS-D7.
Table 5 | Passive immunization and challenge of complement deficient mice.
mAb Number of complement deficient mice surviving Total (%) P
Hours post challenge
0 24 48 72 96
CS-D7 25 15 6 6 2 2 (8%) ∗0.097
CS-D7·N297A 25 11 7 5 0 0 (0%) †0.33
20C2HA 25 9 5 3 0 0 (0%)
∗Comparison of survival with CS-D7 versus survival with isotype control 20C2HA.
†Comparison of survival with CS-D7·N297A versus survival with CS-D7.
CS-D7 MEDIATED ENHANCED SURVIVAL MAY AFFECT cytokine
LEVELS POST CHALLENGE IN THE BLOOD AND THE ORGANS
CS-D7 mediated efficacy may be reflected in a modulation of
cytokine levels. To investigate this possibility, Balb/c mice were
passively immunized and challenged as above. At designated time
points, groups of mice were sacrificed and blood and tissue har-
vested. A selection of cytokines, representing T helper subsets, or
having pro-inflammatory properties, were evaluated. Cytokines
INFγ (Th1), IL17 (Th17), IL5 (Th2), IL6 (pro-inflammatory
mediator), and KCGRO (pro-inflammatory chemokine) were
evaluated post challenge. IL17 and IL5 concentrations did not
change over time for both the blood and the organs, and were
equivalent between CS-D7 treated mice and 20C2HA treated
mice (data not shown). Of the cytokines IFN-γ, IL6, and KCGRO,
there was a trend toward higher IFN-γ in mice treated with CS-
D7. In the sera at 24 and 48 h post challenge (P = 0.03) (Table 7),
Frontiers in Cellular and Infection Microbiology www.frontiersin.org March 2012 | Volume 2 | Article 36 | 7
Pancari et al. Efficacy mechanism of mAb CS-D7
Table 6 | Passive immunization and challenge of P47 phox−/− (neutrophil impaired) mice.
mAb Number of P47 phox−/− mice surviving Total (%) P
Hours post challenge
0 24 48 72 96
CS-D7 10 10 6 3 1 1 (10%) ∗0.95
CS-D7·N297A 10 10 4 3 2 2 (20%) †0.95
20C2HA 10 10 4 3 2 2 (20%)
∗Comparison of survival with CS-D7 versus survival with isotype control 20C2HA.
†Comparison of survival with CS-D7·N297A versus survival with CS-D7.
FIGURE 5 | Bacteria burden in murine tissue post immunization and
challenge with S. aureus. Balb/c mice were passively immunized with
CS-D7 (circles) or isotype control 20C2HA (squares) or PBS alone (triangles),
and 2 h later were challenged via the tail vein with S. aureus SA025. At
designated time points, subsets of animals were sacrificed and the blood and
organs were harvested. Tissue bacterial burden was evaluated by
homogenization of each organ in a total of 5mL PBS and plating of 50μL
homogenate on TSA. The CFU count per 50μL is plotted. For blood CFU
determination, 10μL of undiluted blood was plated. Data shown are means
and ranges from mice (n = 4) in two experiments.
and in the kidney (P = 0.05), liver (P = 0.008), and spleen (P =
0.08) at 24 h post challenge (Table 8), IFN-γ levels were higher
in CS-D7 treated mice. There was also a trend toward lower IL6
levels, which was observed at 4 h (P = 0.005), 24 h (P = 0.0004),
and 48 h in the sera, and at 1 h in the kidney (P = 0.011). At
24 h post challenge, KCGRO was reduced in the blood of CS-D7
treated mice. However, there was no trend with this cytokine at
other times or in other organs.
DISCUSSION
Clearance of bacteria from the blood stream is of vital impor-
tance in host defense against disseminated infection. Bacteria
removal and killing occurs after opsonization with antigen
specific antibody and/or complement. Both the innate (e.g.,
complement) and the adaptive (e.g., antibody) arms of the
immune system cooperate in this function, indicating its evolu-
tionary importance. A central method of bacterial removal from
the bloodstream is mediated through binding to CR1 on erythro-
cytes (Edberg et al., 1992; Lindorfer et al., 2001a,b). Complement
(C3b) opsonized S. aureus is carried to the liver by binding to
CR1 on erythrocytes, where bacteria are taken up and removed
by phagocytic cells of the reticuloendothelial system. Kupffer cells
express CRIg, which is believed to be the capture receptor of
complement opsonized bacteria (Helmy et al., 2006). Opsonized
bacteria may be passed from erythrocytes, or captured directly
from blood, by Kupffer cells. CRIg binds both C3b and iC3b.
Neutrophils are called to the liver by chemokines and cytokines
such as IL8 and IL17. Upon arrival at sites of bacterial residence,
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Table 7 | Serum cytokine levels after passive immunization with one
of two mAbs and challenge with S. aureus SA025.
Cytokine (Time post pg cytokine/mL serum mean
challenge, h) (std dev), n = 5
CS-D7 20C2HA
IFN-γ (0) 0 (0)∗ 0 (0)∗
(4) 3 (3) 11 (12)
(24) 79 (40) 42 (24)
(48) 54 (24)† 22 (16)
IL6 (0) 0 (0)∗ 1 (6)∗
(4) 114 (53)‡ 209 (38)
(24) 73 (27)§ 195 (50)
(48) 295 (157) 412 (343)
KCGRO (0) 20 (18)∗ 48 (36)∗
(4) 760 (57) 634 (163)
(24) 365 (127)∗∗ 570 (169)
(48) 574 (182) 426 (180)
∗P < 0.001 comparing cytokine concentration at time 0 to time points 4, 24, and
48 h.
†P = 0.03 comparing IFN-γ concentration in CS-D7 treated versus 20C2HA
treated animals at 48 h.
‡P = 0.005 comparing IL6 concentration in CS-D7 treated versus 20C2HA
treated animals at 4 h post challenge.
§P = 0.0004 comparing IL6 concentration in CS-D7 treated versus 20C2HA
treated animals at 24 h post challenge.
∗∗P = 0.04 comparing KCGRO concentration at time 24h in CS-D7 treated
versus 20C2HA treated animals.
neutrophils may release DNAnets to capture bacteria (Hickey and
Kubes, 2009; Pilsczek et al., 2010). In the presence of antigen spe-
cific Ab, bacteria may be phagocytosed by different sets of effector
cells, such as neutrophils and tissuemacrophages, expressing both
the FcγR and complement receptors. Binding of the two types of
receptors is synergistic and greatly facilitates uptake and killing
(Liszewski and Atkinson, 1993). Therefore, the presence of anti-
gen specific Ab is a great advantage to the host for pathogen
clearance. CS-D7 has high specificity and affinity for its target,
S. aureus IsdB. IsdB is surface expressed in iron restricted envi-
ronments, such as found in the human host, and as such has been
proposed as a vaccine target (Kuklin et al., 2006; Stranger-Jones
et al., 2006). Passively administered anti-IsdB Ab has demon-
strated efficacy in rodent models (Ebert et al., 2010; Kim et al.,
2010), however, in active immunization with IsdB, Ab response
is not involved in protection in the murine sepsis model (Joshi
et al., 2012). Therefore, it was of importance to determine the
mechanism of protection mediated by the mAb CS-D7.
In an effort to determine if CS-D7 mediates protection by
interfering with bacteria growth, S. aureus was cultured under
in vivo conditions in the presence of CS-D7. The expression of
IsdB is highly upregulated under this optimal in vivo environ-
ment with more than 50% of cells expressing antigen by 4 h,
and essentially 100% of cells expressing the antigen by 8 h post
implantation into rats.We found that during growth in implanted
chambers, in which bacterial and host proteases may be present
in high concentrations, the antigen remained available for anti-
body binding for the length of observation, 48 h. Expression of
IsdB, in the presence of excess CS-D7, did not impact outgrowth
of bacteria, implying that IsdB was not necessary for outgrowth
under these conditions, or that the mAb binding to IsdB did not
interfere with growth. However, the presence of CS-D7 did lead
to transient aggregation of the bacteria under those conditions.
It is possible that CS-D7 could mediate protection by interfer-
ing with heme uptake by the bacteria. The CS-D7 binding region
on IsdB (aa 50–285) spans the domain 1 NEAT motif (aa 140–
269) (Ebert et al., 2010). MAb binding to IsdB did not appear to
interfere with heme transfer from human hemoglobin to IsdB in
vitro. Since heme binding occurs through the domain 2 NEAT
motif (aa 337–462), this may not be surprising (Muryoi et al.,
2008). Kim and co-authors recently published data indicating
that rabbit polyclonal antibodies to IsdB inhibited hemoglobin
binding to IsdB. Their observations may relate to the use of
polyclonal antibodies which would bind multiple epitopes on
IsdB, whereas, CS-D7 recognizes a single epitope which may not
obstruct hemoglobin binding.
Next, the functional activity of CS-D7 Fc was examined. Based
on the current understanding of bacteria clearance, itwas expected
that CS-D7 would mediate protection through binding to its cog-
nate antigen, inducing complement fixation through the classical
pathway, and enhancing uptake and killing by phagocytes. To test
this hypothesis, the mAb was mutated with a point mutation at
aa 297. As expected, after mutation, the mutein did not mediate
binding to FcγR nor did it fix complement in human serum (as
measured by C3b production), whereas the wild type mAb did
possess these functions. Activity in the OP assay was also dra-
matically reduced, essentially equivalent to the isotype control
mAb. The mutein was then compared to the wild type mAb for
protective efficacy. Unexpectedly, themuteinwas as effective as the
wild type mAb at enhancing survival in the murine sepsis model.
Further testing was performed to explore the mechanism of
action of CS-D7 and the mutein. To confirm that Fc binding
to FcγR was not critical for mAb efficacy, passive immuniza-
tion experiments were conducted in FcγR deficient mice. In both
FcγII−/− or FcγRIII−/− mice, both mAbs conferred equivalent
protection, which was significantly more than the isotype control
mAb. Overall survival in these deletion mice was lower than for
wild type Balb/c mice. This may be due to defects in multiple cell
types in the deletion mice (e.g., NK, macrophages, neutrophils,
mast cells, and basophils in the FcγRIII−/−), amplifying the
effects of the challenge dose. Based on the challenge experiments,
mAb binding to either the stimulatory or the inhibitory FcγR was
not essential for in vivo efficacy. It was demonstrated that mutein
CS-D7.N297A did not fix C3b in vitro, in the presence of C1q
replenished human sera. To confirm that activation of the classical
pathway was not necessary for in vivo mAb efficacy, mouse com-
plement component C3 was depleted using CVF (Liszewski and
Atkinson, 1993). It was observed that in the absence of C3, nei-
ther CS-D7 nor CS-D7.N297A enhanced survival in the murine
sepsis model. Therefore, C3 was a critical component for mAb
mediated survival in this model. Since CVF also depletes the host
of the alternative complement components, the presence of that
pathway may also be important in this model.
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Table 8 | Tissue homogenate cytokine levels after passive immunization with one of two mAbs and challenge with S. aureus SA025.
Cytokine; (Time post challenge, h) pg cytokine/mL tissue homogenate mean (std dev), n = 5
CS-D7 20C2HA
Liver Spleen Kidney Liver Spleen Kidney
IFN-γ(0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 1 (1)
(1) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0)
(2) 31 (18) 6 (5) 0 (0) 15 (9) 13 (9) 0 (0)
(4) 20 (17) 28 (4)∗ 7 (13) 21 (13) 90 (29) 4 (5)
(24) 22 (12)∗ 23 (14)∗ 8 (6)∗ 3 (3) 9 (7) 1 (1)
(48) 7 (5) 3 (2) 1 (2) 2 (3) 1 (1) 1 (1)
IL6 (0) 0 (1) 0 (0) 1 (2) 0 (1) 0 (0) 1 (2)
(1) 3 (7) 5 (6) 2 (5)† 25 (20) 11 (8) 41(6)
(2) 19 (17) 3 (3) 0 (0) 9 (6) 4 (5) 0 (0)
(4) 5 (3) 25 (17) 15 (19) 8 (11) 26 (8) 1 (1)
(24) 7 (16) 2 (2) 10 (19) 2 (3) 0 (0) 19 (13)
(48) 16 (6) 1 (2) 190(148) 8 (8) 1(1) 140 (197)
KCGRO (0) 6 (3) 2 (1) 1 (2) 6 (3) 2 (1) 1 (2)
(1) 263 (127) 285 (105) 84 (24) 679 (296) 389 (218) 135 (95)
(2) 403 (122) 159 (80) 35 (8) 367 (206) 201 (84) 44 (11)
(4) 271 (144) 338 (75) 132 (70) 345 (78) 309 (185) 123 (71)
(24) 131 (58) 114 (68) 90 (55) 204 (87) 120 (52) 72 (19)
(48) 463 (208) 192 (85) 137 (106) 283 (203) 192 (120) 210 (297)
∗Comparison of IFN-γ concentrations between mice treated with CS-D7 and mice treated with 20C2HA; Spleen at 4 h: P = 0.002; Spleen at 24 h: P = 0.076; Liver
at 24 h: P = 0.008; Kidney at 24 h: 0.05.
†Comparison of IL6 concentrations between mice treated with CS-D7 and mice treated with 20C2HA; Kidney at 1 h: P = 0.011.
Excess CS-D7, but not the isotype control, led to transient
aggregation of S. aureus in the in vivo growth chamber, in parallel
to an increase in IsdB expression. The aggregates are equivalent
to IC. It is known that IC formation stimulates the activation of
C3 to C3b and iC3b. In fact, one of the main functions of C3b
is to bind to IC and reduce deposits of IC aggregates in small
blood vessels (Liszewski and Atkinson, 1993). Therefore, CS-D7
may stimulate formation of C3b and iC3b through cross linking
of the bacteria, as opposed to stimulation of the classical com-
plement cascade. However, mere binding of a mAb to IsdB does
not necessarily yield efficacy, as demonstrated previously for cer-
tain murine IsdB-specific mAbs (Brown et al., 2009). Therefore,
the potential to bind IsdB in such a way as to produce cross link-
ing of bacteria and complement activation may be important for
efficacy.
Phagocytic cells were essential for mAb efficacy in vivo. When
phagocytes (neutrophils and macrophages) were rendered non-
functional by effectively deleting the oxidative burst mechanism
(in P47 phox−/− mice), efficacy of the mAbs was abrogated. To
further investigate bacteria clearance in the presence of CS-D7,
blood and organ bacteria burden were measured post immu-
nization and challenge. Differences in bacterial burden between
CS-D7 treated and isotype control treated mice were observed in
the liver, at 1 and 4 h post challenge. The liver is the primary organ
responsible for clearance of blood born S. aureus, therefore, this
observation suggests CS-D7 efficacy involves enhanced bacteria
killing in the liver. Lack of more obvious differences in bacteria
burden in other tissue may have several explanations. The
S. aureus inoculum used to challenge mice in the sepsis model
does not have IsdB expressed on its surface, due to culture of
the bacteria on TSA. The expression of IsdB occurs over the
course of several hours in vivo. Thus, antibody binding to IsdB
on the bacteria takes place over several hours (Ebert et al., 2010).
Additionally, a large challenge dose was necessary to produce
sepsis in this model, and individual mice clear bacteria at dif-
ferent rates. Therefore, it may be difficult to capture a time at
which expression of IsdB, leading to mAb mediated clearance
of the bacteria, can be clearly observed; i.e., at any time, there
may be only subtle differences in bacterial burden between CS-D7
and 20C2HA immunized animals. This subtle difference can be
observed in the data shown in Figure 5, for example in the kid-
ney. However differences in the CFU burden in these filter organs
were not statistically significant. Lastly, although CFU measure-
ments indicate similar numbers of viable bacteria, some or most
of these may be sequestered in phagocytic cells in CS-D7 treated
animals, potentially rendering them less able to cause pathologic
sequelae leading to death of the animal.
Previously it was demonstrated that although CS-D7 confers
enhanced survival in Balb/c mice, SCID mice (on a CB-17 back-
ground), lacking lymphocytes, were not protected after passive
transfer of mAb (Joshi et al., 2012). There is increasing evidence
that T cells play an active role in IgG mediated efficacy against
pathogens such as Cryptococcus neoformans, Francisella tularensis,
and Pseudomonas aeruginosa (Casadevall and Pirofski, 2003).
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T cell secretion of certain cytokines or chemokines may be essen-
tial to IgG mediated protection. IL17 is known to stimulate
neutrophils, which is important for neutrophil opsonophagocy-
tosis and killing. It has been demonstrated that IL17 is critical for
protection from S. aureus infection in non-immunized mice, as
well as for IsdB immunized mice (Ishigame et al., 2009; Cho et al.,
2010; Joshi et al., 2012). Therefore, the concentrations of several
cytokines including IL17 were evaluated in the blood and organs
of passively immunized and challenged mice. Inmice treated with
CS-D7 there was a higher level of IFN-γ in the sera and organs,
observed at 24 h post challenge. T cells are the major source for
IFN-γ, thus confirming the observed essential need for T cells
in this model. IFN-γ is a potent activator of phagocytic cells,
especially macrophages, inducing increased microbicidal activity.
This activity could explain the observed enhanced clearance of
S. aureus in the liver. An additional possibility for the mecha-
nism of CS-D7 would be to prevent or damp down a cytokine
storm post challenge. In that case, pro-inflammatory cytokines
should be decreased in blood and organs. Lower levels of IL6,
a potent pro-inflammatory cytokine, were measured in the sera
and kidneys. The observed reduction of IL6 levels support the
existence of a reduced pro-inflammatory or acute phase response
in the CS-D7 treated mice. There was a single time point at
which reduced KCGRO was observed (at 24 h in the sera), but
at all other time points levels in sera and tissues were not signifi-
cantly different between CS-D7 treated animals and controls. This
most likely reflects the importance for neutrophil recruitment
and function in this model, in the presence of either CS-D7 or
control mAb. Importantly, IL17 levels were not measurably stim-
ulated in either the blood or tissues. Therefore, the role of IL17
is either not important, or is yet undefined for mAb mediated
protection in this model. Additionally, the Th2 cytokine IL5 was
not measurably stimulated in these animals.
In summary, we have demonstrated that CS-D7 mediated
protection in the murine sepsis model is dependent on comple-
ment, phagocytes and lymphocytes, but was not dependent on
Fc functionality, classical complement activation, or direct inhi-
bition of bacterial growth. The mechanism of CS-D7 mediated
protection in this model may be triggered by cross linking, or
aggregation, of S. aureus in vivo. Although this mechanism may
not seem relevant to physiological infections, it may play a pre-
viously un-appreciated role in bacterial clearance under certain
circumstances. When bacteria are localized to a site in which repli-
cation leads to large numbers, Ab may bind and aggregate the
cells, leading to enhanced complement deposition and uptake
by neutrophils or tissue macrophages. Additionally, during cer-
tain bloodstream infections, bacteria cross-linked by Ab (IC) may
become aggregated and enhance the deposition of complement.
Therefore, IsdB specific Ab may play a role in the murine sepsis
model, and perhaps in human infection, by enhancing com-
plement fixation on invading S. aureus through a non-classical
mechanism. Importantly, in vitro assays designed to evaluate the
supposed function of Abs may be inadequate or even misleading
for predicting in vivo efficacy. Therefore, careful investigation of
the mechanism of efficacy should be performed in order to design
appropriate in vitro assays for testing Ab potency.
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APPENDIX
HEME BINDING UPTAKE ASSAY
An assay was developed to assess whether IsdB specific mAb
CS-D7 could block IsdB from binding to immobilized heme
(containing iron). Reagents used in the binding assay included
IsdB prepared free of heme (IsdB−), or containing heme,
(IsdB+), human hemoglobin prepared from fresh erythrocytes,
hemoglobin:Sepharose® (hemoglobin was cross-linked to acti-
vated Sepharose® after preparation from fresh human packed
red blood cells), test mAb and isotype matched negative con-
trol mAb 20C2HA. The antibody and IsdB− were combined,
allowing the antibody to bind to the antigen. This combi-
nation was then exposed to hemoglobin (via passage over a
hemoglobin:Sepharose® column) to determine whether the test
antibody could prevent heme transfer from the hemoglobin to
the IsdB− antigen. The IsdB− or IsdB−/antibody passing through
the hemoglobin column was evaluated for acquisition of heme
(iron) by monitoring the antigen complex at 400 nm (the peak
of absorbance for iron, no absorbance by protein). Column frac-
tions were also monitored for protein content by measuring
absorbance at 280 nm (no iron absorption at this wavelength).
The assay procedure was as follows: IsdB− was combined in a
1:1 molar ratio with one of the monoclonal antibodies. After a
short incubation, the antigen/antibody complex was applied to
the hemoglobin-Sepharose column. Column flow through was
collected andmonitored for absorbance at 400 nm, and at 280 nm.
In preliminary experiments, IsdB− was evaluated for
acquisition of heme iron from human hemoglobin in the absence
of Ab. IsdB− was passed over a hemoglobin:Sepharose® column
(sample 1, Table A1). The absorbance at 400 nm indicated that
the initially heme free IsdB− contained little iron until the pro-
tein was exposed to immobilized hemoglobin. It was observed
that although a portion of the IsdB− passed through the column
(not binding to the matrix), a portion bound tightly to the col-
umn (sample 1, Table A1). In further tests, it was determined that
8M urea was required to completely elute the sample from the
hemoglobin-Sepharose®. Removal of hemoglobin from the gel
matrix by 8M urea was minimal (as determined by SDS PAGE).
Urea did completely remove the starting sample (as demonstrated
by SDS PAGE). Both the IsdB− flowing through the column, and
the urea eluted IsdB− demonstrated an increase in absorbance
at 400 nm, indicating acquired iron. Absorbance at A400 for both
flow through and elution fractions was essentially at the back-
ground level if mAb CS-D7 was applied to the column in the
absence of IsdB−.
A fully heme loaded IsdB+ sample was also applied to
the hemoglobin column (sample 2, Table A1), and it was
observed that this material consisted of two fractions also,
one which bound tightly to the column, and one which did
not bind. These data indicated that the heme loaded form of
IsdB behaved similarly to the heme free antigen with regard
to interaction with the immobilized hemoglobin, as did the
heme free antigen. For simplification purposes, the two frac-
tions were combined (i.e., for analysis of results, the flow
through was combined with the urea eluted sample, see text and
Table 1).
Table A1 | IsdB interaction with immobilized human hemoglobin.
No. Sample Starting sample Flow through Eluted material Total, post column fractions
A400/A280 (ratio) A400/A280 A400/A280 A400/280 (ratio)
1. IsdB− 0.06/0.82(0.07) 0.35/0.43 0.49/0.42 0.84/0.85(0.99)
2. IsdB+ 0.82/0.95(0.87) 0.59/0.50 0.58/0.38 1.18/0.88(1.34)
FIGURE A1 | S. aureus cultured in growth chambers in vivo.
S. aureus Becker was placed in growth chambers made from
dialysis tubing aseptically placed under the skin of rats.
At designated times, rats were sacrificed and growth
chambers removed for quantitation of CFU (squares) by serial
dilution and plating on TSA, and for quantitation of surface
expression of IsdB (circles) by flow cytometry (% of cells positive
for IsdB).
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